Latest news

• Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

  Pfizer has paused enrolment for a phase 2 trial evaluating its anti-BCMA bispecific antibody elranatamab, following three cases of peripheral neuropathy in an ongoing phase 1 study. ... The company announced the pause for the MagnetisMM-3 trial, which is

• GSK’s anti-BCMA drug leads crowded CHMP recommendations

  The anti-BCMA therapy has received a positive opinion for the treatment of relapsed and refractory multiple myeloma in patients who no longer respond to treatment with an immunomodulatory agent, a ... The positive recommendation from the CHMP means that

• FDA begins speedy review of BMS’ CAR-T liso-cel

  In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for multiple myeloma. ... However, on that front there are a number of rivals already developing anti-BCMA therapeutics,

• FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

  If approved will become first BCMA targeting drug for myeloma. GlaxoSmithKline looks set to win the race to bring a BCMA-targeting drug to market for multiple myeloma, after gaining a ... This includes belantamab mafodotin, which is a particularly

• GSK files anti-BCMA drug for myeloma after second trial win

  GSK reckons it has the advantage of a solid lead over the other anti-BCMA drug therapies, while GSK2857916 also sidesteps the serious and sometimes life-threatening toxicity that is associated ... and an anti-CD38 antibody – and will try to move the